Evolus, Inc. filings document financial results and corporate disclosures for a Nasdaq-listed performance beauty company focused on aesthetic injectables. Its 8-K reports furnish quarterly and preliminary results, disclose capital-structure actions such as the termination of an at-the-market sales agreement, and record financing arrangements including a senior secured asset-based revolving credit facility.
The company’s proxy and current reports also cover governance and compensation matters, including a classified board structure, director reclassification, officer appointments and departures, equity award plans, executive compensation, shareholder meeting proposals, and related-party disclosures tied to its public-company reporting obligations.
Evolus, Inc. reported first-quarter 2026 results showing modest revenue growth but continuing losses. Total net revenues were $73.1 million, up from $68.5 million a year earlier, driven mainly by Jeuveau and Evolysse product sales. The company posted a net loss of $10.7 million, an improvement from a $18.9 million loss in the prior-year quarter, with loss per share narrowing to $0.16 from $0.30. Cash and cash equivalents were $49.8 million and operating activities used $10.0 million of cash. Evolus’ balance sheet shows total assets of $220.6 million, long-term debt of $156.4 million and a stockholders’ deficit of $28.8 million. Management believes its cash, expected operating cash flows and access to a $30 million asset-based revolving credit facility plus up to $250 million of Pharmakon term loans are sufficient to fund operations for at least the next 12 months. The company highlights ongoing risks including reliance on Jeuveau and Evolysse, significant competition in aesthetics, regulatory dependencies on partners Daewoong and Symatese, required milestone and royalty payments, and a history of accumulated deficits.
Evolus, Inc. reported first quarter 2026 net revenue of $73.1 million, up 7% from a year earlier, driven by $66.4 million of toxin revenue and $6.7 million from injectable HA gels. Gross margin was 66.9%, and adjusted gross margin 68.0%.
The company posted a GAAP operating loss of $6.8 million and net loss of $10.7 million, but achieved positive Adjusted EBITDA of $0.6 million, its second consecutive quarter of positive adjusted profitability. Cash and cash equivalents were $49.8 million as of March 31, 2026.
Evolus reaffirmed 2026 guidance for net revenue of $327–$337 million, adjusted gross margin of 65.5–67.0%, non‑GAAP operating expenses of $210–$216 million, and a low‑ to mid‑single digit Adjusted EBITDA margin. The company also terminated an unused $50 million at‑the‑market equity sales agreement.
Evolus, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 11, 2026 at 8:00 a.m. Pacific Time. Holders of 65,854,751 shares of common stock as of April 14, 2026 may attend online, vote and submit questions via webcast.
Stockholders will elect two Class II directors, Brady Stewart and board chair Vikram Malik, to serve until the 2029 meeting, ratify the appointment of Ernst & Young LLP as independent auditor for 2026, and cast an advisory “say‑on‑pay” vote on compensation for named executive officers. The board recommends voting FOR all three proposals.
The proxy also outlines Evolus’ governance practices, including a majority‑independent board, fully independent key committees, an insider trading policy, a clawback policy tied to accounting restatements, and an enterprise risk management program overseen by the board and its committees. Non‑employee directors receive cash retainers and equity awards in restricted stock units and stock options.
The Vanguard Group amended its Schedule 13G to report that it beneficially owns 0 shares (0%) of Evolus Inc. common stock following an internal realignment. The filing cites the SEC Release No. 34-39538 disaggregation guidance and states certain Vanguard subsidiaries will report separately after the realignment.
The amendment clarifies voting and dispositive powers as 0 and notes the change in reporting structure that led to separate beneficial‑ownership filings by former Vanguard divisions.
Evolus, Inc. officer Rui Avelar reported an open-market sale of 3,119 shares of common stock at a weighted average price of $4.75 per share. According to the filing, these shares were sold under a pre-arranged Rule 10b5-1 trading plan to cover tax withholding obligations from restricted stock unit settlements. Following the sale, Avelar directly holds 427,423 Evolus shares, indicating this was a relatively small, tax-related transaction rather than a large discretionary sale.
Evolus, Inc. director and officer David Moatazedi reported an open-market sale of 13,669 shares of common stock at a weighted average price of $4.7501 per share. According to the filing, the trades were executed under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the settlement of restricted stock unit awards. After these transactions, Moatazedi directly holds 604,700 Evolus shares, indicating this was a relatively small, tax-driven adjustment to his overall equity position.
Evolus, Inc. director and officer David Moatazedi reported a mix of equity compensation vesting and related share sales. On March 16, 2026, 67,489 performance restricted stock units (PSUs) vested and settled into the same number of common shares after achievement of 100% of target performance on a 134,977-PSU award granted on February 7, 2024. The remaining 67,488 PSUs from that grant are scheduled to vest on February 7, 2027, subject to continued service.
On March 17, 2026, he sold 116,720 shares of common stock in open-market transactions at a weighted average price of $4.8883 per share. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations tied to the vesting and settlement of multiple PSU and restricted stock unit awards. Following these transactions, Moatazedi directly held 618,369 shares of Evolus common stock.
Evolus, Inc. executive Rui Avelar reported a routine mix of equity vesting and tax-related share sales. On March 16, 2026, 8,804 performance restricted stock units vested and converted into common shares at a conversion price of $0.0000 per share, with 8,802 PSUs scheduled to vest on February 7, 2027 subject to continued service. On March 17, 2026, he sold 29,996 common shares at a weighted average price of $4.8883 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations tied to multiple PSU and restricted stock unit awards. Following these transactions, he directly holds 430,542 shares of Evolus common stock.
Evolus, Inc. reported a technical change to its board structure. After a prior director departure created an imbalance among its three director classes, the board reclassified director Vikram Malik from Class III to Class II on March 13, 2026 to restore an even distribution.
To accomplish this, Malik briefly resigned as a Class III director and was immediately reappointed as a Class II director, with his board service remaining continuous. He continues as Chairman of the Board and a member of the Compensation Committee, with no new equity awards and existing grants vesting under their original terms.